Shionogi & ViiV Healthcare: CIPO Refuses HIV Integrase Inhibitor Patent CA2955957A1
Canada’s patent office refused application CA2955957A1, covering synthesis routes for carbamoylpyridone HIV integrase inhibitors, finding claim 8 indefinite and all 13 claims not patentably distinct from four claims of the already-granted CA2,606,282. The applicants retain a six-month window to appeal to the Federal Court of Canada.
CIPO refuses HIV integrase inhibitor application on double-patenting and indefiniteness
Shionogi & Co., Ltd and ViiV Healthcare Company jointly sought Canadian patent protection for CA2955957A1, an application directed at the synthesis of carbamoylpyridone HIV integrase inhibitors and key intermediates — a chemically significant class of antiretroviral compounds. The Patent Appeal Board reviewed the application and issued findings adverse to the applicants on two distinct grounds. The Commissioner of Patents adopted those findings in full, issuing the refusal decision on 22 August 2025.
The Commissioner refused the application under section 40 of the Patent Act on two grounds: first, claim 8 was found indefinite and non-compliant with subsection 27(4), which requires claims to define the invention distinctly and explicitly; second, claims 1 through 13 were found not patentably distinct from claims 123, 124, 315 and 316 of the applicants’ own already-granted Canadian Patent 2,606,282, engaging the doctrine of obviousness double-patenting. Because the refusal rests on both procedural and substantive invalidity grounds, both deficiencies would need to be addressed on any appeal.
The applicants now have six months under section 41 of the Patent Act to appeal to the Federal Court of Canada, suggesting the resolution of this matter may be deferred to judicial review. The public record does not disclose whether amendments to narrow claim 8 or to differentiate from CA2,606,282 were proposed during prosecution. The double-patenting finding is particularly notable given that both applicants hold the parent patent — the Board’s conclusion that their own earlier claims render the new application obvious-type double-patented suggests limited room to distinguish without substantive claim amendment.
Filing to Unpatentable in 0 days
Closed 22 August 2025 — CIPO administrative proceeding
CIPO refusal: what the double-patenting and indefiniteness findings mean
Obviousness double-patenting: owning the parent is no defence
Canadian obviousness double-patenting bars an applicant from securing a second patent whose claims are not patentably distinct from their own earlier grant — even where the same entity holds both. Here, claims 1–13 of CA2955957A1 were found indistinct from four specific claims of CA2,606,282. This is a substantive, not merely procedural, bar: the applicants cannot cure it simply by disclaiming the parent or adjusting prosecution timelines.
Obviousness double-patentingSix-month Federal Court appeal window is the primary remaining path
Under section 41 of the Patent Act, Shionogi and ViiV Healthcare have six months from the refusal date to appeal to the Federal Court of Canada. The dual-ground refusal — indefiniteness and double-patenting — means an appeal must address both findings to succeed. If no appeal is filed, or if the appeal fails, the synthesis claims in CA2955957A1 will not be separately patentable in Canada, narrowing the applicants’ patent thicket around this compound class.
s.41 Federal Court appeal availableClaim 8 indefiniteness compounds the double-patenting problem
Beyond double-patenting, claim 8 independently fails subsection 27(4) of the Patent Act for indefiniteness — it does not define the invention distinctly and in explicit terms. This creates a separate prosecution deficiency that must be resolved through redrafting or cancellation of claim 8. The indefiniteness finding affects the claim set’s internal coherence and could independently sustain the refusal even if the double-patenting ground were overcome on appeal.
s.27(4) indefiniteness — claim 8Antiretroviral IP scope narrows where parent patent claims dominate
This refusal suggests that prosecution strategies for continuation-style applications covering HIV integrase inhibitor synthesis face heightened double-patenting scrutiny in Canada when a broad parent patent is already in force. For competitors and generic manufacturers, the refusal reinforces that CA2,606,282 — not CA2955957A1 — remains the operative patent boundary. Any freedom-to-operate analysis for carbamoylpyridone integrase inhibitor synthesis in Canada should focus on the parent patent’s granted claim scope.
CA2,606,282 governs FTO analysisFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Shionogi & Co, Ltd & ViiV Healthcare Company (Re) | Company | Pharmaceutical joint applicants — holders of CA2955957A1 (HIV integrase inhibitor synthesis)Search in Eureka ↗ |
| Defendant | Defendant | Individual | No defendant — ex parte CIPO patent prosecution and refusal proceedingSearch in Eureka ↗ |
| Plaintiff law firm | NORTON ROSE FULBRIGHT CANADA LLP | Law Firm | Representing Shionogi & Co, Ltd & ViiV Healthcare Company (Re)Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | CIPOSearch in Eureka ↗ |
Official order — verbatim text
The Commissioner adopted the Patent Appeal Board’s findings in their entirety, refusing the application on two independent and cumulative grounds. The explicit citation of claims 123, 124, 315 and 316 of CA2,606,282 as the double-patenting comparators is notable — it identifies the precise claim integers that define the patentability ceiling for CA2955957A1. The indefiniteness finding against claim 8 under s.27(4) operates as a separate, self-standing basis for refusal, meaning neither ground alone is dispositive of the appeal outcome. The section 41 reference in the decision signals the Commissioner’s awareness that this is not final — the Federal Court remains available as a check on the Commissioner’s exercise of discretion.
CA2955957A1 — Synthesis of carbamoylpyridone HIV integrase inhibitors
CA2955957A1 is a Canadian patent application directed at the synthesis of carbamoylpyridone HIV integrase inhibitors and their key synthetic intermediates. Carbamoylpyridone-based integrase strand transfer inhibitors (INSTIs) represent a clinically important class of antiretroviral agents, with compounds in this structural family forming the backbone of modern HIV treatment regimens. The application’s claims 1–13 cover synthetic methodology that is closely related to subject matter already protected under CA2,606,282, the applicants’ earlier-granted Canadian patent.
The refusal decision effectively confirms that CA2,606,282 holds the dominant Canadian patent position for this compound class. For competitors operating in the HIV antiretroviral synthesis space — including generic manufacturers seeking to develop non-infringing synthesis routes — the claims 123, 124, 315 and 316 of CA2,606,282 represent the primary patent barrier identified by CIPO. The failure of CA2955957A1 to expand beyond that granted scope suggests the applicants’ prosecution strategy did not successfully carve out additional patentable territory through this application.
Should you run an FTO against CA2955957A1 and CA2,606,282?
Any company developing, manufacturing, or commercialising carbamoylpyridone HIV integrase inhibitors — or structurally related synthetic intermediates — in Canada should assess freedom to operate against CA2,606,282, which CIPO has now confirmed is the controlling patent for this chemical space. Because CA2955957A1 has been refused, it does not grant enforceable rights, but the parent patent’s specifically cited claims (123, 124, 315, 316) define the active risk perimeter. Generic antiretroviral developers and CDMOs should prioritise mapping their synthesis pathways against those exact claims.
PatSnap Eureka’s FTO Search Agent can accelerate this analysis by automatically identifying claim language in CA2,606,282 that reads on carbamoylpyridone synthesis steps, flagging structural analogs in the prior art, and surfacing any subsequent divisional or continuation filings by Shionogi or ViiV Healthcare in Canada. Monitoring the Federal Court docket for a CA2955957A1 appeal filing — which could introduce amended claims — is equally important: Eureka’s litigation monitoring tools can alert your team if new claim scope emerges through the appeal process.
Run a freedom-to-operate analysis on CA2955957A1 to assess your product’s exposure
Run FTO in Eureka →Similar CIPO proceedings: HIV integrase inhibitor and antiretroviral patent disputes
Explore comparable CIPO patent refusals and double-patenting proceedings in the HIV antiretroviral and integrase inhibitor space, including related Federal Court appeals.
What this case signals for the antiretroviral IP landscape in Canada
CIPO’s double-patenting refusal clarifies the outer boundaries of HIV integrase inhibitor synthesis patent protection under Canadian law.
Canadian obviousness double-patenting applies even when the applicant owns the parent
This refusal confirms that Canadian patent law does not permit self-collision immunity: applicants who already hold broad claims in a granted patent cannot secure overlapping claims in a later application without demonstrating patentable distinction. R&D teams seeking continuation-type protection in Canada must perform rigorous claim differentiation analysis against their own portfolio before filing.
CA2,606,282 is now the controlling patent for carbamoylpyridone integrase inhibitor FTO
With CA2955957A1 refused, freedom-to-operate analyses for synthesis of carbamoylpyridone HIV integrase inhibitors in Canada should anchor on the granted claims of CA2,606,282 — specifically claims 123, 124, 315 and 316 which were cited as the double-patenting basis. Generic and biosimilar developers should map their synthesis routes against those specific claim integers.
Shionogi v Defendant — key questions answered
CIPO refused CA2955957A1 on two grounds: claim 8 was found indefinite under subsection 27(4) of the Patent Act, and claims 1–13 were found not patentably distinct from claims 123, 124, 315 and 316 of the applicants’ own granted Canadian Patent 2,606,282 — engaging the doctrine of obviousness double-patenting. Both grounds independently support the refusal.
Obviousness double-patenting prevents an applicant from obtaining a second patent covering subject matter that would have been obvious over their own earlier patent. In this case, the Commissioner found that claims 1–13 of CA2955957A1 were not patentably distinct from four specific claims in CA2,606,282, which Shionogi and ViiV Healthcare already hold. The doctrine applies even when the same entity owns both patents.
Yes. Under section 41 of the Patent Act, the applicants have six months from the refusal date (22 August 2025) to appeal the Commissioner’s decision to the Federal Court of Canada. The Federal Court typically reviews legal questions from CIPO on a correctness standard, and mixed fact-law findings on a reasonableness standard.
The Commissioner’s decision specifically identified claims 123, 124, 315 and 316 of Canadian Patent 2,606,282 as the basis for the obviousness double-patenting finding. These four claims define the patentability ceiling against which claims 1–13 of CA2955957A1 were measured and found indistinct.
Because CA2955957A1 has been refused and grants no enforceable rights, FTO analysis for carbamoylpyridone HIV integrase inhibitor synthesis in Canada should focus on CA2,606,282 — particularly claims 123, 124, 315 and 316 cited in the refusal. Generic developers and CDMOs should map their synthesis routes against those specific claim integers and monitor any Federal Court appeal proceedings that could introduce amended claim scope.
PatSnap Eureka searches patents and litigation data to answer instantly.